Date: 2014-08-25
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at European Society of Cardiology Congress 2014
Company: Boehringer Ingelheim (Germany)
Product: Pradaxa® (dabigatran etexilate mesylate)
Action mechanism:
Disease: patients with non-valvular atrial fibrillation (NVAF)
patients who have experienced deep venous thrombosis (DVT) and pulmonary embolism (PE)
Therapeutic area: Cardiovascular diseases
Country:
Trial details:
Latest
news: * On August 25, 2014, Boehringer Ingelheim Pharmaceuticals announced that data from nine company-sponsored Pradaxa® (dabigatran etexilate mesylate) studies will be presented at the European Society of Cardiology (ESC) Congress 2014, August 30 to September 3 in Barcelona, Spain. The abstracts will feature data about the use of dabigatran in patients with non-valvular atrial fibrillation (NVAF) and for patients who have experienced deep venous thrombosis (DVT) and pulmonary embolism (PE). Other presentations also highlight findings from pharmacokinetic and pharmacodynamics studies on dabigatran. Global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation: baseline characteristics of the first 10,000 patients in GLORIA™-AF Phase II (M. Huisman); Abstract No. 896 Favorable effects of dabigatran versus warfarin on renal function change over time in patients with atrial fibrillation: results from the RE-LY® Trial (M. Bohm); Abstract No. 5686 Dabigatran-induced anticoagulant and bleeding effects can be reversed with both prothrombin complex concentrates and a specific antidote (idarucizumab) in a lethal porcine polytrauma model (O. Grottke); Abstract No. 4844 Pharmacokinetics and pharmacodynamics of dabigatran etexilate 75 mg BID in patients with severe chronic kidney disease: prospective validation of a post hoc determined dose (J. Kooiman); Abstract No. P2427 Activated prothrombin complex concentrate reverses dabigatran-induced bleeding in a lethal porcine polytrauma model (O. Grottke); Abstract No. P3625 Antithrombotic treatment pattern and baseline characteristics of dabigatran and vitamin K antagonist cohorts in North America - The GLORIA-AF registry program (M. Huisman); Abstract No. P4394 Treatment of acute pulmonary embolism with dabigatran or warfarin: A pooled analysis of efficacy data from RE-COVER® and RE-COVER II™ (M. Feuring); Abstract No. P5509 Pharmacokinetic and pharmacodynamic effects of ticagrelor and dabigatran etexilate coadministration in healthy male volunteers (M. Lobmeyer); Abstract No. P6490 Dabigatran versus warfarin in patients with pacemaker or defibrillator wires in the RE-LY trial: the role of contact activation (M. Brueckmann); Abstract No. P6274
